Cancer Clinical Trials

Thanks to our affiliation with Cedars-Sinai, our cancer center is able to offer local patients access to certain clinical trials. When you participate in a clinical trial, you can play a more active role in your own health care, gain access to new research treatments before they are widely available, and help us develop new medical treatments and cures for diseases.

Through the power of clinical trials, our researchers discover new opportunities for advancement in cancer research. Whether testing a drug, device, vaccine or other therapy, our goal remains the same. We want to find better ways to treat people with cancer.

The below cancer clinical trials are currently available, close to home. Ask your doctor if you qualify to help advance your own cancer care and the care of future cancer patients by participating in a clinical trial.

Clinical Trials Open at Huntington Cancer Center

• A012103 – OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
  • Site Primary Investigator: Tina Wang, M.D.
  • link to study
• A012303 – Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade (ShortStop Her2)
  • Site Primary Investigator: Niki Tank, M.D.
  • link to study
• EA7222 – A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
  • Site Primary Investigator: James Hu, M.D.
  • link to study
• GS-US-595-6184– A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05)
  • Site Primary Investigator: Yuan Yuan, M.D.
  • link to study
• IIT2023 -09-Chung-UpfrontTAD – Upfront TAD/SNB in T1-2N0 ER+ Her2- Breast Cancer With Ultrasound-Detected Nodal Metastases
  • Site Primary Investigator: Jeannie Shen, M.D.
  • link to study
• IIT2024-09-Yuan-NeoIVO-Phase II Trial of Ivonescimab in combination with carboplatin + docetaxel in Patients with Early Stage Triple Negative Breast Cancer
  • Site Primary Investigator: Yuan Yuan, M.D.
  • link to study
• NRG-BR009 – A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Pre-menopausal Patients (OFSET)
  • Site Primary Investigator: Niki Tank, M.D.
  • link to study
• NRG-CC008 – A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
  • Site Primary Investigator: Paul Lin, M.D.
  • link to study
• NRG-GY032– A Phase II Study of Tailored Adjuvant Therapy in Pole-Mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (Rainbo Blue and Taper)
  • Site Primary Investigator: Paul Lin, M.D.
  • link to study
• S2206 – Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  • Site Primary Investigator: Niki Tank, M.D.
  • link to study
• S2212 – Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
  • Site Primary Investigator: Tina Wang, M.D.
  • link to study

All the above clinical trials are available at Huntington Cancer Center in Pasadena. Ask your oncologist if there are any other available that might be right for you. To find all cancer trials available at Cedars-Sinai Cancer, click here.